ST-400 (gene-edited cell therapy for beta-thalassemia)
GPTKB entity
Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
investigational therapy
gene-edited cell therapy |
| gptkbp:administeredBy |
autologous transplantation
|
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:developedBy |
gptkb:Sangamo_Therapeutics
|
| gptkbp:geneTargeted |
gptkb:BCL11A
|
| https://www.w3.org/2000/01/rdf-schema#label |
ST-400 (gene-edited cell therapy for beta-thalassemia)
|
| gptkbp:indication |
gptkb:beta-thalassemia
|
| gptkbp:mechanismOfAction |
gene editing of autologous hematopoietic stem cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
clinical development
|
| gptkbp:technology |
Zinc Finger Nuclease (ZFN)
|
| gptkbp:bfsParent |
gptkb:Sangamo_Therapeutics
|
| gptkbp:bfsLayer |
7
|